Latest:
Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer
Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Andrew A. Lane, MD, PhD
Latest:
Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential
Dr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.
Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center
Latest:
Future Directions for the Management of HR+ Breast Cancer
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Andrew D. Smith
Latest:
Melanoma Expert Focuses on Finding the Next Best Therapy
Clinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.
Andrew Hendifar, MD, MPH
Latest:
Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer
Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).
Andrew J. Armstrong, MD
Latest:
ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Andrew J. Armstrong, MD, ScM, FACP, presented 5-year follow-up data from the ARCHES trial showing that enzalutamide plus androgen-deprivation therapy significantly prolonged overall survival versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer, with consistent benefit across subgroups and no new safety signals.
Andrew J. Roth
Latest:
Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment
William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.